Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID) has awarded three grants to Sequella.
Subscribe to our email newsletter
The three new grants, combined with other grants renewed for 2011, brings total non dilutive R&D funding for 2011 to $4.8m, with an additional $3.3m committed for future years.
Out of all three grants, a $3.8m 5-year R01 grant has been awarded to identify and develop new ethylenediamine-based antibiotics for Clostridium difficile, an emerging infectious pathogen causing life-threatening gastrointestinal disease.
The rest of the two grants will support Sequella in its planned Phase 3 clinical studies and develop clinical sites in Russia, the Commonwealth of Independent States and Eastern Europe for evaluation of SQ109 in multi-drug resistant tuberculosis (MDR-TB) and to investigate a new drug target in Mycobacterium tuberculosis.
SQ109, identified as the lead drug candidate from among 63,000 diamine compounds synthesized in a combinatorial chemistry program, is currently under US IND.
SQ109 completed three phase 1 studies in the US and is currently being evaluated in Phase 2 efficacy studies in TB patients in Africa.